Mitochondrial Peptide Reverses Age-Related Aortic Degeneration in Mice
Background
As the body ages, the aorta, the main artery carrying blood from the heart, becomes stiffer and less compliant. This age-related stiffening significantly increases the risk of serious cardiovascular conditions such as aneurysmal disease, hypertension, and diastolic dysfunction. Given that mitochondrial dysfunction is a recognized hallmark of aging and plays a role in other non-age-related aortic diseases, this study aimed to determine if mitochondrial dysfunction directly drives age-related degeneration of the thoracic aorta.
Results
The study found compelling evidence that elamipretide significantly improved mitochondrial function and reduced markers of aortic degeneration in aged mice. ELAM treatment successfully restored complex II-linked respiration (a key measure of mitochondrial energy production) in aged mice to levels comparable to those observed in young mice, while also improving relative phosphorylative flux. ELAM treatment restored complex II-linked respiration in aged mice to values seen in young mice, indicating a reversal of age-related mitochondrial decline. Furthermore, the peptide treatment significantly reduced inflammatory MMP9 (matrix metalloproteinase 9, an enzyme involved in tissue remodeling and inflammation) expression and decreased the number of elastin breaks in the aortas of aged mice. Bulk RNA sequencing analysis revealed that ELAM treatment profoundly affected the aortic transcriptome in an age-dependent manner, leading to a reduction in the expression of senescent and associated pro-inflammatory genes.
Why It Matters
This research provides strong evidence that mitochondrial dysfunction is a primary driver of aortic aging, offering a novel understanding of age-related cardiovascular decline. The successful restoration of mitochondrial function and reduction of inflammatory markers by elamipretide suggests that targeting mitochondria could be a powerful therapeutic strategy. This discovery could pave the way for new pharmacological interventions to prevent or reverse age-related aortic degeneration and associated cardiovascular diseases. Future steps should include further preclinical studies to optimize dosing and efficacy, followed by human clinical trials (e.g., Phase II) to evaluate elamipretide's potential in human patients.